ARCA biopharma Inc. (NASDAQ:ABIO) and Cronos Group Inc. (NASDAQ:CRON), both competing one another are Biotechnology companies. We will compare their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARCA biopharma Inc.	N/A	0.00	7.93M	-0.82	0.00
Cronos Group Inc.	N/A	0.00	N/A	-0.03	0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for ARCA biopharma Inc. and Cronos Group Inc.

Profitability

Table 2 shows ARCA biopharma Inc. and Cronos Group Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
ARCA biopharma Inc.	0.00%	0%	0%
Cronos Group Inc.	0.00%	0%	0%

Analyst Ratings

Recommendations and Ratings for ARCA biopharma Inc. and Cronos Group Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
ARCA biopharma Inc.	0	0	0	0.00
Cronos Group Inc.	1	1	0	2.50

On the other hand, Cronos Group Inc.’s potential upside is 12.27% and its average target price is $20.5.

Institutional & Insider Ownership

Roughly 15.4% of ARCA biopharma Inc. shares are owned by institutional investors while 17.34% of Cronos Group Inc. are owned by institutional investors. ARCA biopharma Inc.’s share owned by insiders are 0.89%. Competitively, Cronos Group Inc. has 5.15% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
ARCA biopharma Inc.	5.75%	9.55%	-15.6%	-24.74%	-36.11%	37.93%
Cronos Group Inc.	5.98%	9.04%	146.67%	68.45%	121.47%	106.54%

For the past year ARCA biopharma Inc. was less bullish than Cronos Group Inc.

Summary

On 4 of the 5 factors Cronos Group Inc. beats ARCA biopharma Inc.

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.